← All trials
NCT03103971
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 17, 2017
- Primary completion
- Jul 17, 2019
- Completion date
- Jul 17, 2033
- First posted
- —
- Last posted
- —
- Enrollment
- 66
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of WashingtonLead sponsor
- National Cancer Institute (NCI)Collaborator
- University of WashingtonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.